Although the detailed mechanism is still unknown, these findings suggest that anti-PD-1/PD-L1 antibodies against melanoma cells might also impair HLA class I/MHC class I expression, which might be canceled by HDAC inhibitors. Here, HDAC9 is linked to melanoma.